Transcriptional changes following treatment with the menin inhibitor revumenib in patients with relapsed or refractory acute leukaemia with 
MRD
RESIDUAL DISEASE, REMISSION
RNA-seq before and after treatment with revumenib, showing downregulation of critical leukaemogenic target genes The rate of complete remission or complete remission with partial haematologic recovery (CR/CRh) was 30% (95% confidence interval (CI) 18.8–43.2) in 18 of 60 evaluable patients with undetectable measurable residual disease (MRD), as assessed by multiparameter flow cytometry, in 14 of 18 patients (78%) who achieved CR/CRh (Fig. 